[144] Aehr Test Systems SEC Filing
Rhea-AI Filing Summary
Aehr Test Systems (AEHR) Form 144 notice reports a proposed sale of 10,000 common shares, with an aggregate market value of $201,600, to be sold through Charles Schwab & Co., Inc. on or about 08/15/2025 on Nasdaq. The shares were acquired on 04/05/2023 via stock option exercise from the issuer and were paid for in cash on the acquisition date. The filer reports no securities sold in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information about the issuer. The filing presents a routine insider sale notification rather than operational or financial results.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider sale; size is immaterial relative to outstanding shares.
The notice documents a proposed disposition of 10,000 shares acquired by stock option exercise and intended to be sold through a registered broker. At an aggregate value of $201,600 against approximately 29.9 million shares outstanding, the sale represents roughly 0.03% of the outstanding common stock, indicating no likely material market impact. This is a compliance-driven disclosure under Rule 144 rather than a signal of corporate performance.
TL;DR: Filing meets Rule 144 disclosure elements; includes required representations and broker details.
The form lists acquisition details (04/05/2023, stock option exercise), payment method (cash), broker name and address, approximate sale date (08/15/2025), and states no sales in the prior three months. The filer also includes the standard attestation regarding material nonpublic information. From a compliance perspective, the form appears complete for the intended transaction.